Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

Positive News for Two Undervalued Firms in the Prohost Portfolio

Exelixis CABOMETYX Approval Exelixis ( EXEL ) partner Ipsen received approval from the European Commission ( EC ) for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma ( DTC ), which is...

May 5, 2022

Voyager Therapeutics: Demonstrating Productivity in Collaboration with Neurocrine to Advance Gene Therapies for Neurological Diseases

Voyager Therapeutics Voyager Therapeutics ( VYGR ) is a biotech company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. The firm’s pipeline includes programs for Alzheimer’s disease, amyotrophic...

April 17, 2024

Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat

Merck in the NEWS Merck Pharmaceuticals ( MRK ) , known as Merck, Sharp & Dohme (MSD) outside the United States and Canada, and the Finnish pharmaceutical Company Orion Corporation announced that notice has been provided of the mutual exercise...

July 2, 2024

The European Commission Approved Regeneron Product Dupixent® as Maintenance Treatment for Adults with Uncontrolled COPD

Regeneron in the NEWS Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) announced that the European Commission ( EC ) has approved Dupixent® (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (...

July 5, 2024

Exelixis First Quarter 2022 Financial Results. See Also: Milestones in Clinical and Pipeline Development

Exelixis Press Release This press release covers a large part of Exelixis accomplishments, including important details about its pipeline products, especially, cabozantinib, in addition to new results from clinical trials. We advise Prohost subscribers to read this press release, so...

May 19, 2022

Vertex and TreeFrog Therapeutics Announced Licensing Agreement and Collaboration to Optimize Production of Vertex Cell Therapies for Type 1 Diabetes

Vertex Pharmaceuticals and TreeFrog Therapeutics in the NEWS Vertex Pharmaceuticals ( VRTX ) and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog’s proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex’s cell therapies for Type...

April 25, 2024

Regeneron and Sanofi: FDA Approves Dupixent® as First Treatment for Eosinophilic Esophagitis

Regeneron Pharmaceuticals and Sanofi Announce FDA Approval of Dupixent ® Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) announced that the U.S. FDA has approved Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis ( EoE ) aged...

May 23, 2022

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Kazia Therapeutics in the NEWS Sydney, July 10, 2024, Kazia Therapeutics Limited ( KZIA ) - an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard...

July 11, 2024

Vertex Pharmaceuticals Reports First Quarter 2024 Financial Results

Vertex Pharmaceuticals Vertex Pharmaceuticals ( VRTX ) reported consolidated financial 2024 results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance. Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex Pharmaceuticals said, “Vertex...

May 7, 2024

Alnylam Pharmaceuticals: Positive New Results of Lumasiran in Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals Alnylam Pharmaceuticals ( ALNY ) led the translation of RNA interference ( RNAi ) into a new class of innovative therapeutics, transforming the lives of people afflicted with rare and prevalent diseases with unmet needs. RNAi is a...

May 25, 2022

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024